. Author manuscript; available in PMC: 2013 Mar 1.

Published in final edited form as: Cancer. 2011 Aug 5;118(5):1412–1421. doi: 10.1002/cncr.26402

Table 6.

Propensity score-adjusted competing-risks regression analysis measuring the association between comprehensive compliance measures and survival.

Surveillance and Treatment Strategy	HR	95% CI
<4 cystoscopy, <4 cytology and no BCG (referent)	1.00	***
<4 cystoscopy, <4 cytology and 1^st instillation of BCG after 90 days	1.62	0.67–3.94
<4 cystoscopy, <4 cytology and 1^st instillation of BCG within 90 days	0.88	0.36–2.11
≥4 cystoscopy, ≥ 4 cytology and no BCG	1.11	0.34–3.60
≥4 cystoscopy, ≥ 4 cytology and 1^st instillation of BCG after 90 days	0.43	0.16–1.16
≥4 cystoscopy, ≥ 4 cytology and 1^st instillation of BCG within 90 days	0.41	0.18–0.93